Paul LePage: DRUG LAWS

In 2015, LePage Refused to Sign a Bipartisan Bill That Strengthened Laws on the Manufacture and Sale of Methamphetamine and Other Drugs. In July 2015, LePage allowed LD1246 to become law without his signature after it passed both chambers without a roll call vote. LD1246 “strengthens laws regarding the manufacture and sale of methamphetamine and other drugs. It does the following: 1. Provides that possession of two grams or more of fentanyl powder or 90 or more individual containers containing fentanyl powder constitutes "trafficking"; 2. Provides that possession of at least one gram but less than two grams of fentanyl powder or at least 45 but fewer than 90 individual containers of fentanyl powder constitutes "furnishing"; 3. Establishes the crime of aggravated unlawful operation of a methamphetamine laboratory; 4. Prohibits and designates as a Class C crime the unlawful possession of a scheduled drug containing fentanyl powder, seven grams or more of cocaine or two grams or more of cocaine in the form of cocaine base; and 5. Authorizes a court to order as part of the sentence of a defendant restitution that to pay as an expense of emergency response the costs of a response to a suspected unlawful methamphetamine laboratory, including trained laboratory personnel and laboratory services.” [Summaries of Bills, LD1246, 2015; Maine State Legislature, LD1246, 2015]

In 2015, LePage Refused to Sign Bipartisan Legislation Adding Two Additional Drugs Related to Fentanyl to the List of Schedule W Drugs. In July 2015, LePage allowed LD729 to become law without his signature after it passed both chambers without a roll call vote. LD729 “adds acetylfentanyl and methylacetylfentanyl derivates to the list of Schedule W drugs. Acetylfentanyl and methylacetylfentanyl derivates are not approved by the United States Food and Drug Administration and are closely related to the prescription opioid fentanyl, which is a Schedule W drug.” [Summaries of Bills, LD729, 2015; Maine State Legislature, LD729, 2015]

Source report (PDF)